Complete financial analysis of PTC Inc. (PTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Inc., a leading company in the Software – Application industry within the Technology sector.
You may be interested
- Canacol Energy Ltd (CNE.TO) Income Statement Analysis – Financial Results
- GetNinjas S.A. (NINJ3.SA) Income Statement Analysis – Financial Results
- General Motors Company (8GM.DE) Income Statement Analysis – Financial Results
- Shikun & Binui Ltd. (SKBN.TA) Income Statement Analysis – Financial Results
- Nanjing Vishee Medical Technology Co., Ltd (688580.SS) Income Statement Analysis – Financial Results
PTC Inc. (PTC)
About PTC Inc.
PTC Inc. operates as software and services company in the Americas, Europe, and the Asia Pacific. The company operates in two segments, Software Products and Professional Services. It offers ThingWorx platform, which offers a set of capabilities that enable enterprises to digitally transform every aspect of their business with innovative solutions that are simple to create, easy to implement, scalable to meet future needs, and designed to enable customers to accelerate time to value; and Vuforia, which enables the visualization of digital information in a physical context and the creation of AR. The company also provides Onshape, a software-as-a-service product development platform unites computer-aided design with data management, collaboration tools, and real-time analytics; Arena, a PLM solution enables product teams to collaborate virtually anytime and anywhere; Creo, a 3D CAD technology enables the digital design, testing, and modification of product models; and Windchill, a product lifecycle management software. In addition, it offers Integrity, an application lifecycle management solution; Servigistics, service parts management solution; and consulting, implementation, training, cloud, and license and support services. The company was formerly known as Parametric Technology Corporation and changed its name to PTC Inc. in January 2013. PTC Inc. was incorporated in 1985 and is headquartered in Boston, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.30B | 2.10B | 1.93B | 1.81B | 1.46B | 1.26B | 1.24B | 1.16B | 1.14B | 1.26B | 1.36B | 1.29B | 1.26B | 1.17B | 1.01B | 938.19M | 1.07B | 941.28M | 854.92M | 720.72M | 660.03M | 671.94M | 741.96M | 934.61M | 928.41M | 1.06B | 1.02B | 808.80M | 600.10M | 394.30M | 244.30M | 163.10M | 86.70M | 44.70M | 25.50M | 11.00M |
| Cost of Revenue | 486.83M | 441.01M | 385.98M | 371.10M | 334.27M | 325.38M | 326.19M | 329.02M | 325.67M | 334.73M | 373.68M | 373.04M | 372.13M | 356.77M | 307.70M | 309.76M | 330.79M | 290.81M | 269.63M | 208.24M | 182.18M | 218.49M | 216.96M | 252.57M | 204.65M | 168.30M | 127.00M | 54.10M | 39.70M | 26.80M | 13.70M | 7.20M | 3.10M | 1.90M | 11.10M | 4.70M |
| Gross Profit | 1.81B | 1.66B | 1.55B | 1.44B | 1.12B | 930.25M | 915.63M | 835.02M | 814.87M | 920.51M | 983.28M | 920.50M | 883.55M | 810.18M | 702.35M | 628.43M | 739.54M | 650.47M | 585.29M | 512.48M | 477.85M | 453.45M | 525.00M | 682.04M | 723.77M | 889.30M | 891.00M | 754.70M | 560.40M | 367.50M | 230.60M | 155.90M | 83.60M | 42.80M | 14.40M | 6.30M |
| Gross Profit Ratio | 78.82% | 78.97% | 80.04% | 79.46% | 77.08% | 74.09% | 73.73% | 71.73% | 71.45% | 73.33% | 72.46% | 71.16% | 70.36% | 69.43% | 69.54% | 66.98% | 69.09% | 69.10% | 68.46% | 71.11% | 72.40% | 67.48% | 70.76% | 72.98% | 77.96% | 84.09% | 87.52% | 93.31% | 93.38% | 93.20% | 94.39% | 95.59% | 96.42% | 95.75% | 56.47% | 57.27% |
| Research & Development | 433.05M | 394.37M | 338.82M | 299.92M | 256.58M | 246.89M | 249.77M | 236.06M | 229.33M | 227.51M | 226.50M | 221.92M | 214.96M | 211.41M | 201.57M | 188.50M | 182.02M | 162.35M | 147.34M | 118.27M | 107.99M | 128.43M | 136.07M | 148.94M | 143.76M | 124.10M | 93.40M | 53.20M | 39.50M | 25.60M | 15.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 232.38M | 233.52M | 204.73M | 206.01M | 159.83M | 127.92M | 142.98M | 145.07M | 145.62M | 218.52M | 142.23M | 131.94M | 117.47M | 110.29M | 92.88M | 80.67M | 87.83M | 79.78M | 77.81M | 63.61M | 58.26M | 69.42M | 67.26M | 166.00K | 0.00 | 62.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 558.95M | 530.13M | 485.25M | 517.78M | 435.45M | 417.45M | 414.52M | 372.95M | 367.47M | 338.78M | 357.45M | 360.64M | 377.80M | 353.05M | 317.53M | 301.37M | 306.88M | 292.22M | 274.29M | 243.76M | 226.05M | 298.48M | 333.25M | 455.42M | 0.00 | 407.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 791.33M | 763.64M | 689.98M | 723.79M | 595.28M | 545.37M | 557.51M | 518.01M | 513.08M | 557.30M | 499.68M | 492.58M | 495.26M | 463.34M | 410.41M | 382.04M | 394.71M | 371.99M | 352.10M | 307.36M | 284.32M | 367.90M | 400.51M | 455.59M | 487.93M | 470.80M | 453.90M | 352.50M | 267.50M | 184.30M | 107.80M | 86.40M | 50.80M | 27.40M | 6.20M | 3.60M |
| Other Expenses | 0.00 | -125.91M | 34.97M | 29.40M | 28.71M | 23.84M | 255.00K | -42.30M | -30.18M | -15.09M | -10.46M | -1.09M | 20.30M | 18.32M | 15.61M | 15.62M | 15.58M | 7.47M | 6.07M | 1.64M | 5.20M | 5.86M | 35.76M | 80.51M | 78.77M | 62.30M | 29.90M | 22.40M | 16.80M | 9.50M | 5.20M | 3.30M | 1.80M | 1.00M | 700.00K | 500.00K |
| Operating Expenses | 1.22B | 1.20B | 1.06B | 1.05B | 880.57M | 816.10M | 838.63M | 786.18M | 775.61M | 820.94M | 758.30M | 740.98M | 730.53M | 693.07M | 627.58M | 586.16M | 592.31M | 541.81M | 505.51M | 427.27M | 397.51M | 502.18M | 572.34M | 685.04M | 710.46M | 657.20M | 577.20M | 428.10M | 323.80M | 219.40M | 128.40M | 89.70M | 52.60M | 28.40M | 6.90M | 4.10M |
| Cost & Expenses | 1.71B | 1.64B | 1.45B | 1.42B | 1.21B | 1.14B | 1.16B | 1.12B | 1.10B | 1.16B | 1.13B | 1.11B | 1.10B | 1.05B | 935.27M | 895.92M | 923.10M | 832.62M | 775.15M | 635.51M | 579.68M | 720.67M | 789.29M | 937.61M | 915.11M | 825.50M | 704.20M | 482.20M | 363.50M | 246.20M | 142.10M | 96.90M | 55.70M | 30.30M | 18.00M | 8.80M |
| Interest Income | 4.40M | 5.40M | 2.50M | 1.80M | 3.80M | 4.10M | 3.82M | 3.25M | 3.44M | 3.70M | 3.12M | 2.86M | 2.92M | 3.84M | 3.01M | 4.56M | 10.06M | 9.87M | 5.44M | 6.88M | 3.48M | 3.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 119.65M | 129.42M | 54.27M | 50.48M | 76.43M | 43.05M | 41.67M | 42.40M | 29.88M | 14.74M | 8.16M | 6.98M | 4.75M | 3.31M | 1.53M | 3.20M | 7.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 141.41M | 137.16M | 122.04M | 122.53M | 80.82M | 77.82M | 87.41M | 86.74M | 86.55M | 84.43M | 77.31M | 76.55M | 66.47M | 62.39M | 62.18M | 61.61M | 60.02M | 39.20M | 33.89M | 25.88M | 35.16M | 41.64M | 72.63M | 76.37M | 78.77M | 62.30M | 29.90M | 22.40M | 16.80M | 9.50M | 5.20M | 3.30M | 1.80M | 1.00M | 700.00K | 500.00K |
| EBITDA | 730.02M | 599.15M | 573.41M | 564.77M | 291.95M | 141.17M | 157.74M | 127.74M | 49.24M | 125.70M | 271.57M | 209.76M | 191.95M | 170.25M | 145.84M | 81.98M | 186.73M | 138.86M | 104.10M | 117.19M | 72.20M | -7.09M | 25.29M | 113.17M | 77.54M | 294.40M | 343.70M | 331.90M | 378.70M | 157.60M | 107.40M | 69.50M | 32.80M | 15.40M | 8.20M | 2.70M |
| EBITDA Ratio | 31.76% | 28.36% | 33.20% | 28.09% | 24.91% | 15.57% | 13.57% | 12.33% | 17.72% | 18.12% | 24.37% | 23.83% | 20.05% | 15.71% | 12.83% | 13.75% | 22.22% | 17.71% | 14.44% | 15.52% | 24.59% | 4.45% | 7.60% | 14.32% | 13.28% | 33.65% | 43.24% | 41.84% | 45.66% | 45.14% | 42.04% | 40.83% | 35.29% | 31.10% | 27.45% | 22.73% |
| Operating Income | 588.06M | 458.47M | 447.36M | 380.75M | 210.86M | 117.66M | 73.24M | 40.90M | -37.01M | 56.16M | 196.58M | 127.32M | 128.10M | 117.11M | 74.78M | 19.30M | 125.25M | 92.77M | 71.73M | 85.79M | 37.42M | -79.63M | -78.49M | -3.00M | 13.31M | 232.10M | 313.80M | 326.60M | 236.60M | 148.10M | 102.20M | 66.20M | 31.00M | 14.40M | 7.50M | 2.20M |
| Operating Income Ratio | 25.58% | 21.86% | 23.14% | 21.07% | 14.46% | 9.37% | 5.90% | 3.51% | -3.25% | 4.47% | 14.49% | 9.84% | 10.20% | 10.04% | 7.40% | 2.06% | 11.70% | 9.86% | 8.39% | 11.90% | 5.67% | -11.85% | -10.58% | -0.32% | 1.43% | 21.95% | 30.83% | 40.38% | 39.43% | 37.56% | 41.83% | 40.59% | 35.76% | 32.21% | 29.41% | 20.00% |
| Total Other Income/Expenses | -119.10M | -125.91M | -50.26M | 11.01M | -76.16M | -42.74M | -43.96M | -43.17M | -30.18M | -15.09M | -10.46M | -1.09M | -7.36M | -12.57M | 7.36M | -2.12M | -6.36M | 6.89M | 3.70M | 5.53M | -377.00K | -2.80M | 4.15M | -5.09M | -32.91M | -50.90M | -109.80M | 10.60M | -95.00M | -20.40M | 4.70M | 2.20M | 2.30M | 1.50M | 1.10M | 100.00K |
| Income Before Tax | 468.96M | 332.57M | 397.10M | 391.76M | 134.71M | 20.30M | 28.66M | -1.41M | -67.19M | 41.07M | 186.11M | 126.23M | 120.74M | 104.55M | 82.14M | 17.17M | 118.89M | 99.66M | 75.43M | 91.31M | 37.04M | -82.43M | -74.34M | -10.86M | -5.07M | 181.20M | 204.00M | 337.20M | 216.10M | 127.70M | 106.90M | 68.40M | 33.30M | 15.90M | 8.60M | 2.30M |
| Income Before Tax Ratio | 20.40% | 15.86% | 20.54% | 21.68% | 9.24% | 1.62% | 2.31% | -0.12% | -5.89% | 3.27% | 13.72% | 9.76% | 9.62% | 8.96% | 8.13% | 1.83% | 11.11% | 10.59% | 8.82% | 12.67% | 5.61% | -12.27% | -10.02% | -1.16% | -0.55% | 17.13% | 20.04% | 41.69% | 36.01% | 32.39% | 43.76% | 41.94% | 38.41% | 35.57% | 33.73% | 20.91% |
| Income Tax Expense | 92.63M | 87.03M | 84.02M | -85.17M | 4.01M | 47.76M | -23.33M | -7.65M | -12.73M | -21.03M | 25.92M | -17.54M | 156.13M | 19.12M | 57.77M | -14.35M | 39.18M | -44.00M | 14.56M | 7.72M | 2.23M | 15.85M | 19.28M | -2.65M | -1.09M | 61.90M | 98.30M | 118.00M | 78.20M | 50.30M | 40.00M | 25.50M | 12.20M | 5.60M | 3.00M | 700.00K |
| Net Income | 376.33M | 245.54M | 313.08M | 476.92M | 130.70M | -27.46M | 51.99M | 6.24M | -54.47M | 62.10M | 160.19M | 143.77M | -35.40M | 85.42M | 24.37M | 31.52M | 79.70M | 143.66M | 60.87M | 83.59M | 34.81M | -98.28M | -93.62M | -8.21M | -3.98M | 119.30M | 86.70M | 219.20M | 137.90M | 77.40M | 66.90M | 42.90M | 21.10M | 10.30M | 5.60M | 1.60M |
| Net Income Ratio | 16.37% | 11.71% | 16.19% | 26.39% | 8.96% | -2.19% | 4.19% | 0.54% | -4.78% | 4.95% | 11.81% | 11.11% | -2.82% | 7.32% | 2.41% | 3.36% | 7.45% | 15.26% | 7.12% | 11.60% | 5.27% | -14.63% | -12.62% | -0.88% | -0.43% | 11.28% | 8.52% | 27.10% | 22.98% | 19.63% | 27.38% | 26.30% | 24.34% | 23.04% | 21.96% | 14.55% |
| EPS | 3.14 | 2.07 | 2.67 | 4.08 | 1.13 | -0.23 | 0.45 | 0.05 | -0.48 | 0.54 | 1.34 | 1.19 | -0.30 | 0.73 | 0.21 | 0.27 | 0.70 | 1.27 | 0.55 | 0.77 | 0.29 | -0.92 | -0.90 | -0.08 | -0.03 | 1.10 | 0.80 | 2.06 | 1.30 | 0.75 | 0.73 | 0.48 | 0.25 | 0.13 | 0.08 | 0.02 |
| EPS Diluted | 3.12 | 2.06 | 2.65 | 4.03 | 1.12 | -0.23 | 0.44 | 0.05 | -0.48 | 0.54 | 1.34 | 1.19 | -0.30 | 0.71 | 0.20 | 0.27 | 0.68 | 1.22 | 0.54 | 0.75 | 0.29 | -0.92 | -0.90 | -0.08 | -0.03 | 1.08 | 0.77 | 2.00 | 1.23 | 0.75 | 0.73 | 0.48 | 0.25 | 0.13 | 0.08 | 0.02 |
| Weighted Avg Shares Out | 119.68M | 118.34M | 117.19M | 116.84M | 115.66M | 117.72M | 116.39M | 115.52M | 113.47M | 115.99M | 119.55M | 120.81M | 118.71M | 117.58M | 115.64M | 114.95M | 113.70M | 112.73M | 109.85M | 108.54M | 120.04M | 106.25M | 104.02M | 101.38M | 116.84M | 108.45M | 108.38M | 106.30M | 106.40M | 103.24M | 92.00M | 90.32M | 84.40M | 82.40M | 74.67M | 75.20M |
| Weighted Avg Shares Out (Dil) | 120.74M | 119.33M | 118.23M | 118.37M | 116.27M | 117.72M | 118.16M | 117.36M | 114.61M | 116.01M | 119.98M | 121.24M | 118.71M | 120.97M | 119.93M | 117.36M | 117.87M | 117.49M | 113.38M | 111.98M | 120.04M | 106.25M | 104.02M | 101.38M | 116.84M | 110.98M | 111.87M | 109.63M | 112.00M | 103.24M | 92.00M | 90.32M | 84.40M | 82.40M | 74.67M | 75.20M |
PTC, Microsoft & Volkswagen Collaborate on Codebeamer AI Copilot
PTC partners with MSFT and Volkswagen for a Codebeamer AI Copilot designed to simplify product development.
PTC Partners with Microsoft and Volkswagen Group to Develop Codebeamer Generative AI Copilot
Collaboration brings together industry leaders to advance generative AI use cases for manufacturing Codebeamer Copilot expected to simplify requirements management as part of the product development process Codebeamer Copilot beta expected to release in early 2025 BOSTON , Dec. 3,...
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder.
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S....
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
WARREN, N.J. , Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the...
PTC Therapeutics discontinues development of ALS drug after trial failure
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.
Source: https://incomestatements.info
Category: Stock Reports